Metagenomi Therapeutics Inc MGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.14
- Day Range
- $1.13–1.22
- 52-Week Range
- $1.13–3.95
- Bid/Ask
- $1.15 / $1.18
- Shares Outstanding
- 37.65M
- Market Cap
- $44.42M
- Volume/Avg
- 100,093 / 184,961
Key Statistics
- Price/Earnings (Normalized)
- 0.18
- Price/Sales
- 2.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 118
- Website
- https://metagenomi.co
Valuation
|
Metric
|
MGX
|
|---|---|
Price/Earnings (Normalized) | 0.18 |
Price/Book Value | 0.33 |
Price/Sales | 2.01 |
Price/Cash Flow | — |
Price/Earnings
MGX
Financial Strength
|
Metric
|
MGX
|
|---|---|
Quick Ratio | 6.23 |
Current Ratio | 6.43 |
Interest Coverage | — |
Quick Ratio
MGX
Profitability
|
Metric
|
MGX
|
|---|---|
Return on Assets (Normalized) | −30.11% |
Return on Equity (Normalized) | −42.13% |
Return on Invested Capital (Normalized) | −37.78% |
Return on Assets
MGX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Cpfsmbrm | Pjmmfm | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rvvwcdkw | Zrmbzy | $64B | |||
| argenx SE ADR
ARGX
| Trhyhpwj | Jcq | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nylvlsblt | Djqzr | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Znkyqgrjj | Qjxxmm | $24B | |||
| BioNTech SE ADR
BNTX
| Bgqltstc | Ggkd | $23B | |||
| Incyte Corp
INCY
| Lbgzwrc | Mjpgx | $22B | |||
| Moderna Inc
MRNA
| Rclsfjbs | Rfp | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Gyklpfwk | Bqrg | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Xrqxlsxbj | Lvys | $13B |
United States